<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167219</url>
  </required_header>
  <id_info>
    <org_study_id>1999LS073</org_study_id>
    <secondary_id>MT1999-20</secondary_id>
    <secondary_id>9911M24961</secondary_id>
    <nct_id>NCT00167219</nct_id>
    <nct_alias>NCT00262756</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)</brief_title>
  <official_title>Hematopoietic Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that long-term disease-free survival (DFS) in patients with
      JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan
      (L-PAM) followed by hematopoietic cell transplantation (HCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six
      times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two
      days, and MELPHALAN via the central venous line for one day. Busulfan, cyclophosphamide, and
      melphalan are given to destroy the subject's leukemia. As well, these drugs will destroy the
      subject's own immune system to help ensure the new bone marrow takes and grows after
      transplantation.

      On the day of transplantation, bone marrow or umbilical cord blood from the donor will arrive
      to the bone marrow transplant unit and be transfused via venous line. These new cells will
      replace the subject's bone marrow.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 1999</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine probability of long-term disease free survival in JMML</measure>
    <time_frame>at 1 year after transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures are the incidence of neutrophil engraftment, graft-versus-host disease (GVHD), regimen-related toxicity, and relapse.</measure>
    <time_frame>at 1 year after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving study regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Transplantation on Day 0.</description>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <other_name>Bone marrow transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preparative Regimen</intervention_name>
    <description>Busulfan
Cyclophosphamide
Mesna
Melphalan
Anti-thymocyte Globulin (ATG)</description>
    <arm_group_label>Intent-to-Treat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of JMML and fulfill these minimal criteria
             (International diagnostic criteria for JMML):

               -  Leukocytosis (&gt; 13,000) with absolute monocytosis (&gt; 1,000)

               -  The presence of immature myeloid cells in the peripheral blood

               -  Less than 30% marrow blasts

               -  Absence of t(9:22) or BCR-ABL transcript

               -  Adequate major organ function including:

                    -  Cardiac: ejection fraction &gt; 45%

                    -  Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy,
                       ascites)

                    -  Karnofsky performance status &gt; 70% or Lansky score &gt; 50%

                    -  Creatinine must be &lt; 2 x normal for age

          -  Written informed consent.

        Exclusion Criteria:

          -  Active uncontrolled infection within one week of HCT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret MacMillan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Nelson, RN</last_name>
    <phone>612-273-2925</phone>
    <email>knelso62@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nelson</last_name>
      <phone>612-273-2925</phone>
      <email>knelso62@fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cell transplant</keyword>
  <keyword>long term survival</keyword>
  <keyword>retinoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

